本帖最后由 老马 于 2012-1-13 21:20 编辑
. c. n" ~" j( }4 T( R; z8 f
8 V3 J6 B I9 s8 ~8 y爱必妥和阿瓦斯丁的比较: I; O/ X3 s, u0 x
4 A% }( o Z/ U5 ^6 ? \http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
) q7 |( t$ {' U0 p
+ f) h% U6 {6 {0 n5 x$ _% Y* V D
' i( \4 d4 n/ H
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
8 g& s6 Y; q3 Q7 w- }% ?==================================================
2 c3 o3 D0 D2 G" \+ rOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
\, L" j" {* EPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
% A% B0 Q9 Z2 d3 u, UResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.: B% _- a0 |& F, X* G; v7 M
|